Scientists at the University of Delaware and the University of Illinois at Chicago have discovered a new way to kill liver cancer cells and inhibit tumor growth. First, silence a key cellular enzyme, then add a potent drug. This research can accelerate the development of new treatments for liver cancer that are currently difficult to cure. Surgery is usually not an option for liver cancer, and the available drugs have limited efficacy. According to the National Institutes of Health, more than 82% of liver cancer patients will die within five years. The researchers cultivated liver 癌細胞 and manipulated the expression of an enzyme called hexokinase-2. Then, the cells were treated with metformin, a diabetes drug that reduces glucose production in the liver. Then, examine how cancer cells respond to the loss of hexokinase-2, an enzyme that helps cells metabolize food-derived glucose. Mass spectrometry was used to analyze cancer cells and then determine the metabolic flux of cells with and without hexokinase-2. They suspected that cells losing hexokinase-2 would starve to death, but surprisingly, targeting hexokinase-2 had only a minor effect on stopping cancer cell growth. Another weapon, metformin, can help stop cancer cells from growing. We show that targeting hexokinase-2 can indeed be a successful strategy for cancer treatment, and that it requires the use of metformin as a second-generation compensation mechanism.Finally, a team from the University of Illinois at Chicago tested the effect of removing the combination of hexokinase-2 and the liver cancer drug sorafenib on liver cancer tumors in mice. This combination was better than the treatment alone.
CART細胞療法
サイトカイン放出症候群を理解する: 原因、症状、治療
サイトカイン放出症候群 (CRS) は、免疫療法や CAR-T 細胞療法などの特定の治療によって引き起こされることが多い免疫系反応です。これにはサイトカインの過剰な放出が含まれ、発熱や倦怠感から臓器損傷など生命を脅かす可能性のある合併症まで、さまざまな症状を引き起こします。管理には慎重な監視と介入戦略が必要です。